News

María Berrocal, MD, titled her Kreissig Award Lecture "Throwing away wisdom: How we abandon what works."

Prof Tunde Peto and Prof Catherine Creuzot-Garcher will serve on an educational panel during the networking event.

Neurotech Pharmaceuticals enhances its leadership by appointing Peter J. McDonnell, MD, a leading ophthalmology expert, to its Board of Directors.

An understanding of GA growth kinetics is key to addressing the pathophysiology of age-related macular degeneration.

Roche's Contivue platform gains EU CE mark, offering innovative treatment for neovascular AMD with fewer injections and promising long-term vision outcomes.

Aleksandra Rachitskaya, MD, FASRS, is a member of the Modern Retina editorial advisory board.

In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration.

This year's EURETINA meeting boasts a crowd of 10,000 attendees, including delegates, industry leaders, and young retina specialists.

Prithvi Ramtohul, MD, is a PhD candidate based in Marseille, France and previously completed a fellowship in Paris under Prof. Tadayoni.

BVI launches Virtuoso, a groundbreaking dual-function surgical platform for cataract and vitreoretinal procedures, enhancing efficiency and control in surgery.

Outlook Therapeutics seeks FDA clarity on ONS-5010 after a complete response letter, aiming to address efficacy concerns for wet AMD treatment.

Where to find members of our editorial board at this year's European Society of Retina Specialists Congress.

Anat Loewenstein, MD, president of EURETINA, announces the EURETINA Innovation Spotlight (EIS) will return on September 3 this year.

Leading companies to unveil new research on retinal diseases at EURETINA 2025, showcasing innovative therapies and clinical trial results.

AMD treatment may become unrecogniable as gene therapies evolve.

identifeye HEALTH unveils a retinal screening platform, enhancing accessibility and efficiency in patient care through innovative technology and AI integration.

The committee will work to help the organization increase awareness and early identification of diabetes-related eye diseases and improve access to eye care treatment, policy development, research, and surveillance.

Catch up on this week's highlights in retina.

FDA issues a complete response letter to Outlook Therapeutics for ONS-5010, citing insufficient evidence of effectiveness for wet AMD treatment.

Researchers used adaptive optics scanning light ophthalmoscopy (AOSLO) to study retinas in mice with photoreceptor damage, specifically photoreceptor laser injury.

Advancements in retinal therapies and technologies are scheduled to be showcased at EURETINA 2025 from Clearside, ZEISS, and Ashvattha Therapeutics.

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration.

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.